Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 10/20 | 0.65 |
| ▸ | MAP4K2 | Q12851 | 10/20 | 0.65 |
| ▸ | ABL1 | P00519 | 2/20 | 0.65 |
| ▸ | BCR | P11274 | 1/20 | 0.65 |
| ▸ | BMX | P51813 | 1/20 | 0.65 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.65 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.65 |
| ▸ | SYK | P43405 | 1/20 | 0.60 |
| ▸ | BTK | Q06187 | 4/20 | 0.53 |
| ▸ | LCK | P06239 | 3/20 | 0.53 |
| ▸ | JAK2 | O60674 | 5/20 | 0.52 |
| ▸ | SRC | P12931 | 4/20 | 0.52 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3144232 | 0.91 | SYK (0.56) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL30338817 | 0.90 | SYK (0.57) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL3135923 | 0.90 | SYK (0.57) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL3132833 | 0.89 | SYK (0.59) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL3139779 | 0.86 | TNK2 (0.62) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL3143228 | 0.85 | KDR (0.52) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL3129666 | 0.84 | TNK2 (0.50) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL4867361 | 0.82 | SYK (0.68) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL3825123 | 0.81 | TNK2 (0.63) | TNK2MAP4K2ABL1BCRBMX | |
| SCHEMBL14070255 | 0.81 | BTK (0.73) | TNK2MAP4K2ABL1BCRBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651648-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-02 | — | — | EP | claimed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | claimed |
| JP-2007500725-A | — | — | 2007-01-18 | — | — | JP | claimed |
| EP-1651648-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-03 | — | — | EP | claimed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | claimed |
| WO-2005011597-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-02-10 | — | — | WO | claimed |
| US-7642255-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-01-05 | — | — | US | disclosed |
| US-7642255-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-01-05 | — | — | US | disclosed |
| US-7642255-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-01-05 | — | — | US | disclosed |
| EP-1651648-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-02 | — | — | EP | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| EP-1651648-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-03 | — | — | EP | disclosed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | disclosed |
| WO-2005011597-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | BMX, FES, FRK | TNK2 203/4885MAP4K2 37/4885ABL1 66/4885 |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BMX, FES, FRK | TNK2 203/4885MAP4K2 37/4885ABL1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.